Octavian Savu1, Viviana Elian2, Oana Steriade2, Ileana Teodoru2, Stela Mihut3, Catalin Tacu3, Adrian Covic4, Cristian Serafinceanu2. 1. "N.C. Paulescu" Institute of Diabetes, Nutrition and Metabolic Diseases, 5-7 Ion Movila, 020475, Bucharest, Romania. savu.octavian@gmail.com. 2. "N.C. Paulescu" Institute of Diabetes, Nutrition and Metabolic Diseases, 5-7 Ion Movila, 020475, Bucharest, Romania. 3. S.C. Diaverum Romania SRL, Bucharest, Romania. 4. C.I. Parhon, Hospital, Iasi, Romania.
Abstract
PURPOSE: We aimed to analyze the impact of basal insulin analogues on glucose variability (GV) in patients with type 2 diabetes (DM) undergoing renal replacement therapy. METHODS: Fourteen subjects on insulin therapy for at least 6 months (detemir, n = 7 vs. glargine, n = 7) were sequentially enrolled in this prospective study. Continuous glucose monitoring system (CGMS Gold, Dex Com 7+) was applied for 5 days, over 3 consecutive sessions of hemodialysis (HD). Various glycemic profiles (coefficient of variation-CV of mean glucose) were compared between the day on (HD-on) and the day off (HD-off) dialysis. The CV of at least 3 values of HbA1c (HPLC) since replacement therapy has been applied to assay the long-term GV. Endogenous insulin and insulin resistance (HOMA using fasting glucose and C-peptide levels), fasting lipid profile, quantitative C-reactive protein (CRP) and ferritin (values adjusted for Hb) were measured in serum at inclusion. RESULTS: The overnight HD-off and HD-on short-term (CV CGMS) GV, overall long-term (CV of HbA1c) GV, CRP and ferritin were reduced in subjects treated with detemir (paired t test, p = 0.0001, 0.0011, 0.036, <0.001, and <0.001 between groups). All participants were insulin-resistant (HOMA-IR > 3). CONCLUSIONS: Insulin-resistant patients with type 2 diabetes undergoing hemodialysis for end-stage renal disease on insulin detemir exhibit lower glycemic variability and pro-inflammatory profile than with insulin glargine.
PURPOSE: We aimed to analyze the impact of basal insulin analogues on glucose variability (GV) in patients with type 2 diabetes (DM) undergoing renal replacement therapy. METHODS: Fourteen subjects on insulin therapy for at least 6 months (detemir, n = 7 vs. glargine, n = 7) were sequentially enrolled in this prospective study. Continuous glucose monitoring system (CGMS Gold, Dex Com 7+) was applied for 5 days, over 3 consecutive sessions of hemodialysis (HD). Various glycemic profiles (coefficient of variation-CV of mean glucose) were compared between the day on (HD-on) and the day off (HD-off) dialysis. The CV of at least 3 values of HbA1c (HPLC) since replacement therapy has been applied to assay the long-term GV. Endogenous insulin and insulin resistance (HOMA using fasting glucose and C-peptide levels), fasting lipid profile, quantitative C-reactive protein (CRP) and ferritin (values adjusted for Hb) were measured in serum at inclusion. RESULTS: The overnight HD-off and HD-on short-term (CV CGMS) GV, overall long-term (CV of HbA1c) GV, CRP and ferritin were reduced in subjects treated with detemir (paired t test, p = 0.0001, 0.0011, 0.036, <0.001, and <0.001 between groups). All participants were insulin-resistant (HOMA-IR > 3). CONCLUSIONS:Insulin-resistant patients with type 2 diabetes undergoing hemodialysis for end-stage renal disease on insulindetemir exhibit lower glycemic variability and pro-inflammatory profile than with insulinglargine.
Authors: Allan J Collins; Robert N Foley; Blanche Chavers; David Gilbertson; Charles Herzog; Kirsten Johansen; Bertram Kasiske; Nancy Kutner; Jiannong Liu; Wendy St Peter; Haifeng Guo; Sally Gustafson; Brooke Heubner; Kenneth Lamb; Shuling Li; Suying Li; Yi Peng; Yang Qiu; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Bryn Thompson; Changchun Wang; Eric Weinhandl; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frank Daniels; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa Journal: Am J Kidney Dis Date: 2012-01 Impact factor: 8.860
Authors: Hye Seung Jung; Hong Il Kim; Min Joo Kim; Ji Won Yoon; Hwa Young Ahn; Young Min Cho; Kook-Hwan Oh; Kwon Wook Joo; Jung Geon Lee; Seong Yeon Kim; Kyong Soo Park Journal: Diabetes Technol Ther Date: 2010-10 Impact factor: 6.118
Authors: J Smith-Palmer; M Brändle; R Trevisan; M Orsini Federici; S Liabat; W Valentine Journal: Diabetes Res Clin Pract Date: 2014-06-23 Impact factor: 5.602
Authors: Sara Kazempour-Ardebili; Varunika L Lecamwasam; Thushara Dassanyake; Andrew H Frankel; Frederick W K Tam; Anne Dornhorst; Gary Frost; Jeremy J O Turner Journal: Diabetes Care Date: 2009-02-05 Impact factor: 17.152
Authors: Ana María Gómez; Santiago Vallejo; Freddy Ardila; Oscar M Muñoz; Álvaro J Ruiz; Mauricio Sanabria; Alfonso Bunch; Elly Morros; Laura Kattah; Maira García-Jaramillo; Fabián León-Vargas Journal: J Diabetes Sci Technol Date: 2017-09-20